Study wrapper · #867
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.
Editor's note
A target-trial emulation in nearly 15,000 propensity-matched patients with established atherosclerotic disease and obesity but no diabetes found GLP-1 receptor agonists associated with lower all-cause mortality, myocardial infarction, and heart-failure hospitalization, with no clear stroke effect. The results align directionally with the randomized SELECT trial, which lends credibility, but semaglutide is analyzed within a mixed GLP-1 class rather than alone, and the authors are explicit that observational data cannot establish causation. Strong complementary real-world signal.
Plain-language abstract
In a large records-based study of people with heart disease and obesity but no diabetes, starting a GLP-1 drug was linked to about a third lower risk of death, heart attack, and heart-failure hospitalization, though stroke risk was not clearly changed.